I am still waiting for the "additional analyses" that were done on the patients in the study in regard to their multi-targeted investigational therapeutic. XOMA 052 is unique since it may "NOT ONLY" help patients control their glucose levels.

Drugs developed through Xoma’s technologies, Cimza and Lucentis, are generating billions of dollars in revenues for their owners, while Xoma is getting a few bucks that it calls royalties. There are no current marketed diabetes drugs aimed at protecting the insulin making cells. Further positive results from XOMA 052 should take the stock price to where it was a few years ago, i.e., over ten times its current stock price.